Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Gains from Sales and Divestitures (2016 - 2025)

Karyopharm Therapeutics' Gains from Sales and Divestitures history spans 11 years, with the latest figure at $230299.0 for Q4 2025.

  • For Q4 2025, Gains from Sales and Divestitures fell 90.55% year-over-year to $230299.0; the TTM value through Dec 2025 reached $230299.0, down 90.55%, while the annual FY2025 figure was $230299.0, 90.55% down from the prior year.
  • Gains from Sales and Divestitures reached $230299.0 in Q4 2025 per KPTI's latest filing, down from $2.4 million in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $957.7 million in Q4 2022 to a low of $230299.0 in Q4 2025.
  • Average Gains from Sales and Divestitures over 5 years is $192.4 million, with a median of $1.1 million recorded in 2023.
  • Peak YoY movement for Gains from Sales and Divestitures: surged 199323.22% in 2022, then tumbled 99.89% in 2023.
  • A 5-year view of Gains from Sales and Divestitures shows it stood at $480249.0 in 2021, then soared by 199323.22% to $957.7 million in 2022, then crashed by 99.89% to $1.1 million in 2023, then soared by 132.04% to $2.4 million in 2024, then plummeted by 90.55% to $230299.0 in 2025.
  • Per Business Quant, the three most recent readings for KPTI's Gains from Sales and Divestitures are $230299.0 (Q4 2025), $2.4 million (Q4 2024), and $1.1 million (Q4 2023).